Welcome to our dedicated page for BIOLIFE SOLUTIONS SEC filings (Ticker: BLFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioLife Solutions SEC filings document material-event disclosures for a Nasdaq-listed life sciences supplier focused on cell processing tools and services for cell and gene therapy. Recent 8-K filings cover unaudited financial results, continuing-operations performance, operational highlights, and Regulation FD investor presentations describing the company’s bioproduction products and CGT market focus.
The filing record also includes governance and corporate-administration disclosures, including stockholder voting results from the annual meeting, director elections, advisory executive compensation votes, auditor ratification, and an officer retirement notice. These filings frame the company’s public reporting around operating results, product-market disclosures, governance matters, and executive-level changes.
BioLife Solutions (BLFS) Form 144 discloses a proposed sale of 500,000 shares of common stock through BMO Capital Markets on NASDAQ with an aggregate market value of $11,185,000. The filing reports 47,905,265 shares outstanding and an approximate sale date of 08/11/2025.
The shares were acquired on 12/16/2020 by purchase from a shareholder and paid in cash. The filing also lists a recent sale by Casdin Partners Master Fund, L.P. of 1,000,000 shares on 06/10/2025 for $23,800,000. The seller certifies they are unaware of any undisclosed material adverse information.
BioLife Solutions Inc. (BLFS) – Form 4 filing: Chief Human Resources Officer Sarah Aebersold sold 198 shares of common stock on 7 July 2025 at $22.27 per share under a pre-established Rule 10b5-1 trading plan. The sale was executed to cover tax-withholding obligations associated with previously vested restricted stock. After the transaction, the officer still owns 78,523 shares, which continue to be held directly. No derivative security activity was reported.
The transaction represents <0.3% of the insider’s total direct holdings and does not indicate a change in her overall investment thesis or role at the company. As such, the filing is considered routine and of low financial materiality for most investors.
BioLife Solutions Inc. (BLFS) – Form 4 insider transaction
Chief Human Resources Officer Sarah Aebersold reported the sale of 711 shares of common stock on 16 June 2025 at a price of $22.23 per share. The transaction was executed under a pre-arranged Rule 10b5-1(c) trading plan that became effective 11 December 2024, indicating the sale was scheduled in advance and not triggered by undisclosed information.
Following the sale, Aebersold’s direct ownership stands at 78,721 shares. Calculations from the disclosed data show the disposal represents roughly 0.9 % of her prior position (79,432 shares), suggesting only a modest reduction in personal exposure to the company’s equity.
No derivative securities were bought or sold and no additional transactions were reported. The filing contains no information about company operations, earnings, or strategic initiatives; it purely documents a routine insider trade.